<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7359800\results\search\testTrace\results.xml">
  <result pre="the most vulnerable to COVID-19 [5,6]. There is no registered" exact="treatment" post="or vaccine for this disease [7]. For the treatment"/>
  <result pre="registered treatment or vaccine for this disease [7]. For the" exact="treatment" post="of affected people, limited urgent use of chloroquine and"/>
  <result pre="The use of an antiviral drug called Favilavir as a" exact="treatment" post="for coronavirus has been approved by the National Medical"/>
  <result pre="are at risk for severe disease and death from SARS-CoV-2" exact="infection" post="[[21], [22], [23]]. Mechanism of immune systems in the"/>
  <result pre="the virus from entering into host cells to limit the" exact="infection" post="and plays a very intense protective role at the"/>
  <result pre="a very intense protective role at the later stage of" exact="infection" post="and prevents relapse of infection. By contrast, a cellular"/>
  <result pre="clinical common sense. They proposed some normal approaches for the" exact="treatment" post="of patients with COVID-19 (Fig. 5 ). They posited"/>
  <result pre="treatment, vaccination, and clinical approaches. Fig. 5 Progression of COVID-19" exact="infection" post="and potential adjuvant interventions [34]. Reasons for failure The"/>
  <result pre="fatal hypercytokinemia with multiorgan failure, and it is underrecognized. Viral" exact="infection" post="triggers sHLH and occurs in 3.7%â€&quot;4.3% of sepsis cases"/>
  <result pre="and muscle pain. One study demonstrated that [42] for the" exact="treatment" post="of COVID-19, convalescent plasma therapy is effective. The survival"/>
  <result pre="with SARS of viral etiology has been improved with this" exact="treatment" post="[43]. Pre-donation assessment is performed to ensure compliance with"/>
  <result pre="SARS-CoV, and MARS-CoV but did occur for Ebola. Reports say" exact="treatment" post="with convalescent plasma for patients with COVID-19 is safe"/>
  <result pre="(H1N1) None [64] Because there is no definite and specific" exact="treatment" post="for patients with COVID-19, some antiviral agents are prescribed"/>
  <result pre="agents, remdesivir is the most well-known potential drug for the" exact="treatment" post="of patients with COVID-19. For the treatment of Ebola"/>
  <result pre="drug for the treatment of patients with COVID-19. For the" exact="treatment" post="of Ebola virus infection in 2017, Gilead Sciences synthesized"/>
  <result pre="of patients with COVID-19. For the treatment of Ebola virus" exact="infection" post="in 2017, Gilead Sciences synthesized and developed remdesivir, and"/>
  <result pre="and similar chemical structures and are often used for the" exact="treatment" post="of malaria erythematosus and rheumatoid arthritis [66]. Lopinavir is"/>
  <result pre="in Russia and used in Russia and China for the" exact="treatment" post="of prophylaxis, infections associated with influenza A and B,"/>
  <result pre="for days 2â€&quot;10, per oral [91] Recent observations of COVID-19" exact="treatment" post="improving the immune system: case study Researchers are attempting"/>
  <result pre="animals with S protein-oriented vaccines is very effective in preventing" exact="infection" post="by homologous coronavirus [94]. If human cells are infected"/>
  <result pre="infection. To assess that phenomenon, they performed a pseudovirus particle-based" exact="neutralization assay." post="Patients #1, 2, 4, and 5, all within the"/>
  <result pre="poses many threats. A different door is used for every" exact="infection" post="to enter a cell, and blocking these routes of"/>
  <result pre="cell, and blocking these routes of entry can stop an" exact="infection" post="before it begins. The immune system neutralizes an infection"/>
  <result pre="an infection before it begins. The immune system neutralizes an" exact="infection" post="by producing antibodies; however, this must be conducted at"/>
  <result pre="conducted at the proper time. An immune systemâ€&quot;ideallyâ€&quot;must stop an" exact="infection" post="before it has established a foothold in the body"/>
  <result pre="[109], [110], [111]]. Fig. 8 The adaptive immune response to" exact="infection" post="[111]. Suggested food, vaccination, drugs, and supplementary for the"/>
  <result pre="Insufficient vitamin D and vitamin E can lead to coronavirus" exact="infection" post="[113]. Vitamin D can be found in sunlight, and"/>
  <result pre="boosting the immune system is a potential resource for the" exact="treatment" post="of patients with COVID-19. The process and mechanism of"/>
  <result pre="bystander type 2 alveolar epithelial cells during influenza A virus" exact="infection" post="reveals in vivo Wnt pathway downregulationJ Virol922018e01325-18 18Wu Z,"/>
  <result pre="Pac J Allergy Immunol38120201932105090 33SusannaFelsensteinHerbert JennyA.McNamara PaulS.Hedrich Chris-tianM.COVID-19: immunology and" exact="treatment" post="optionsClin Immunol2152020108448 34ShiY.WangY.ShaoC.COVID-19 infection: the perspectives on immune responsesCell"/>
  <result pre="-CamposM.BaillieJ.K.The effectiveness of con-valescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
  <result pre="bystander type 2 alveolar epithelial cells during influenza A virus" exact="infection" post="reveals in vivo Wnt pathway downregulationJ Virol922018e01325-18 46ManuelRojasYhojanRodrÃ­guezabMonsalvea DianaM.AcostaAmpudia"/>
  <result pre="47BinZhangShuyiLiuTanTan.WenhuiHuangYuhaoDongLuyanChenTreatment with convalescent plasma for critically ill patients with SARS-CoV-2" exact="infection" post="chest2020 48ShenC.WangZ.ZhaoF.YangY.LiJ.YuanJ.Treatment of 5 critically ill patients with Covid-19"/>
  <result pre="Sci352020e14932281317 52SooY.O.Y.ChengY.WongR.HuiD.S.LeeC.K.TsangK.K.S.Retrospective comparison of convalescent plasma with continuing high-dose methyl-prednisolone" exact="treatment" post="in SARS patientsClin Microbiol Infect10200467667815214887 53ChengY.WongR.SooY.O.Y.WongW.S.LeeC.K.NgM.H.L.Use of conva-lescent plasma"/>
  <result pre="Hong KongEur J Clin Microbiol Infect Dis242005444615616839 54NieQ.-H.-H.LuoX.-D.-D.HuiW.-L.-L.Advances in clinical" exact="diagnosis" post="and treatment of severe acute respiratory syndrome worldJ Gastroenterol9200311391143"/>
  <result pre="J Clin Microbiol Infect Dis242005444615616839 54NieQ.-H.-H.LuoX.-D.-D.HuiW.-L.-L.Advances in clinical diagnosis and" exact="treatment" post="of severe acute respiratory syndrome worldJ Gastroenterol9200311391143 55YehK.-M.-M.ChiuehT.-S.-S.SiuL.K.LinJ.-C.-C.ChanP.K.S.PengM.-Y.-Y.Experi-ence of"/>
  <result pre="workers in a Taiwan hospitalJ Antimicrob Chemother56200591992216183666 56ZhouX.ZhaoM.WangF.JiangT.LiY.NieW.Epidemiologic features, clinical" exact="diagnosis" post="and therapy of first cluster of patients with severe"/>
  <result pre="Ebola virus disease in GuineaN Engl J Med3742016334226735992 61HungI.F.ToK.K.LeeC.-K.-K.LeeC.-K.-L.ChanK.YanW.-W.-W.Convalescent plasma" exact="treatment" post="reduced mortality in patients with severe pandemic influenza A"/>
  <result pre="experi-ence on the use of extracorporeal membrane oxygenation for the" exact="treatment" post="of influenza A (H1N1)Hong Kong Med J16201044745421135421 63YuH.GaoZ.FengZ.ShuY.XiangN.ZhouL.Clinical characteristics"/>
  <result pre="human cases of highly pathogenic avian influenza A (H5N1) virus" exact="infection" post="in ChinaPLoS One32008e298518716658 64KongL.K.ZhouB.P.Successful treatment of avian influenza with"/>
  <result pre="avian influenza A (H5N1) virus infection in ChinaPLoS One32008e298518716658 64KongL.K.ZhouB.P.Successful" exact="treatment" post="of avian influenza with convalescent plasmaHong Kong Med J122006489"/>
  <result pre="phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the" exact="treatment" post="of Ebola and emerging virusesJ Med Chem60520171648166128124907 66RynesR.Antimalarial drugs"/>
  <result pre="Ebola and emerging virusesJ Med Chem60520171648166128124907 66RynesR.Antimalarial drugs in the" exact="treatment" post="of rheumatological diseasesRheumatology3671997799805 67https://www.accessdata.fda.gov/drugsatfdadocs/label/2019/021251s058slp. KALETRA (lopinavir and ritonavir) tablet.12/2019."/>
  <result pre="Acad, Ser B, Phys Biol Sci9372017449463 70McClellanK.PerryC.M.Oseltamivir Drugs612200126328311270942 71WhitleyR.J.HaydenF.G.ReisingerK.S.YoungN.DutkowskiR.IpeD.Oral oseltamivir" exact="treatment" post="of influenza in childrenPediatr Infect Dis J202200112713311224828 72WuR.WangL.KuoH.D.An update"/>
  <result pre="and pro-jection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect"/>
  <result pre="severe COVID-19N Engl J Med2020(April) 84ChuC.M.ChengV.C.C.HungI.F.N.WongM.M.L.ChanK.H.ChanK.H.S.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax593200425225614985565 85ChanJ.F.YaoY.YeungM.L.DengW.BaoL.JiaL.Treatment with"/>
  <result pre="corona virus disease 2019: a retrospective cohort studyJ Infect2020(March) 89SissokoD.LaouenanC.FolkessonE.MLebingÂ´A.B.BeavoguiA.H.BaizeS.Exper-imental" exact="treatment" post="with favipiravir for Ebola virus disease (the JIKI Trial):"/>
  <result pre="essential interrelationArch Biochem Biophys6112016586527021581 115JinY.H.CaiL.ChengZ.S.ChengH.DengT.FanY.P.A rapid advice guide-line for the" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia"/>
  <result pre="Biochem Biophys6112016586527021581 115JinY.H.CaiL.ChengZ.S.ChengH.DengT.FanY.P.A rapid advice guide-line for the diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)Mil"/>
 </snippets>
</snippetsTree>
